News | May 03, 2025
Sanofi Consumer Healthcare India Q1 PAT up 12.9%
The Q1 2025 also witnessed a successful launch of Allegra D
The Q1 2025 also witnessed a successful launch of Allegra D
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Bayer expects 2025 to be the most difficult year of its turnaround
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
Subscribe To Our Newsletter & Stay Updated
